Neurology
-
Randomized Controlled Trial
Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.
To determine whether oral quinacrine increases survival in sporadic Creutzfeldt-Jakob disease (sCJD). ⋯ This study provides Class I evidence that quinacrine does not improve survival for people with sCJD when given orally at a dose of 300 mg per day for 2 months.